1. Home
  2. WNEB vs XBIT Comparison

WNEB vs XBIT Comparison

Compare WNEB & XBIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Western New England Bancorp Inc.

WNEB

Western New England Bancorp Inc.

HOLD

Current Price

$13.99

Market Cap

264.8M

Sector

Finance

ML Signal

HOLD

Logo XBiotech Inc.

XBIT

XBiotech Inc.

N/A

Current Price

$2.17

Market Cap

66.8M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
WNEB
XBIT
Founded
1853
2005
Country
United States
United States
Employees
N/A
N/A
Industry
Savings Institutions
Pharmaceuticals and Biotechnology
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
264.8M
66.8M
IPO Year
2001
2015

Fundamental Metrics

Financial Performance
Metric
WNEB
XBIT
Price
$13.99
$2.17
Analyst Decision
Buy
Analyst Count
3
0
Target Price
★ $13.67
N/A
AVG Volume (30 Days)
43.4K
★ 43.6K
Earning Date
04-28-2026
05-08-2026
Dividend Yield
★ 2.00%
N/A
EPS Growth
★ 33.93
N/A
EPS
★ 0.42
N/A
Revenue
★ $44,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$7.25
N/A
P/E Ratio
$33.02
★ N/A
Revenue Growth
★ N/A
N/A
52 Week Low
$10.78
$2.09
52 Week High
$15.01
$3.44

Technical Indicators

Market Signals
Indicator
WNEB
XBIT
Relative Strength Index (RSI) 55.14 40.04
Support Level $13.34 N/A
Resistance Level $14.14 $2.48
Average True Range (ATR) 0.36 0.04
MACD 0.02 0.00
Stochastic Oscillator 75.27 15.38

Price Performance

Historical Comparison
WNEB
XBIT

About WNEB Western New England Bancorp Inc.

Western New England Bancorp Inc through its bank subsidiary, provides a range of financial services to individuals and companies in western Massachusetts and northern Connecticut. These services include commercial lending, residential lending and consumer lending, checking, savings and time deposits, cash management, and wealth management. Substantially all of the company's revenues, profits, and assets are derived by the Bank from banking products and services.

About XBIT XBiotech Inc.

XBiotech Inc is a biopharmaceutical company that discovers and develops True Human monoclonal antibodies derived from human donors to replicate the human immune response in the treatment of various diseases. It has developed a pipeline of product candidates using True Human antibodies targeting both inflammatory and infectious diseases. The company's developement pipeline comprises: Natrunix, an antibody targeting IL-1a in oncology (pancreatic cancer), a clinical stage therapeutic for Methicillin Resistant Staphylococcus aureus (MRSA), and several pre-clinical stage therapeutics, including: an oral delivery antibody therapeutic for colon infection by C. difficile; an injectable therapy for varicella zoster (adult chicken pox), the causative agent for shingles; and an influenza therapy.

Share on Social Networks: